# Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

> **NCT00331409** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 23 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00331409
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331409, "Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00331409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*